An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infectionKevin P. Egan, Harvey M. Friedman, Gary H. Cohen et al.|PLoS Pathogens|2020Cited by 65
A Trivalent HSV-2 gC2, gD2, gE2 Nucleoside-Modified mRNA-LNP Vaccine Provides Outstanding Protection in Mice against Genital and Non-Genital HSV-1 Infection, Comparable to the Same Antigens Derived from HSV-1Kevin P. Egan, Harvey M. Friedman, Giulia Tebaldi et al.|Viruses|2023Cited by 28
Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infectionKevin P. Egan, Sita Awasthi, Lauren M. Hook et al.|Human Vaccines & Immunotherapeutics|2020Cited by 15
Novel Adjuvant S-540956 Targets Lymph Nodes and Reduces Genital Recurrences and Vaginal Shedding of HSV-2 DNA When Administered with HSV-2 Glycoprotein D as a Therapeutic Vaccine in Guinea PigsSita Awasthi, Harvey M. Friedman, John M. Lubinski et al.|Viruses|2023Cited by 3
Preventing neonatal herpes: Protection after maternal mRNA-lipid nanoparticle vaccination equals or exceeds that from prior maternal genital infection in murine modelsAngela Desmond, Harvey M. Friedman, John M. Lubinski et al.|The Journal of Immunology|2022Cited by 0